Positive BRCA1/2 status is a survival advantage

Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations – the National Israeli Study of Ovarian Cancer

https://doi.org/10.1016/j.ygyno.2019.02.022

Women with invasive epithelial ovarian cancer who are carriers of BRCA1/2 mutation have lower 5, 10, and 15 years all-cause mortality than non-carriers.

In the first 5  years, being a carrier was associated with a 26% reduction in mortality compared to non-carriers.

For women who survived 5  years and more, being a BRCA carrier was not associated with better survival in the subsequent years.